Author

Rashmi Bhatnagar

Institution: Syneos Health (India)

Observed institutions: Syneos Health (United States), Syneos Health (India)

OpenAlex ID: A5111443571

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

2023 · Paula Rodríguez Otero, Sikander Ailawadhi, et al. · Blood · 16

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

2023 · Rachid Baz, Paula Rodriguez Otero, et al. · Blood · 5

Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Subanalysis of Black Patients (pts)

2024 · Krina K. Patel, Paula Rodríguez-Otero, et al. · Transplantation and Cellular Therapy · 2

P-031 Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy

2023 · Salomon Manier, Paula Rodriguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

Extended Treatment-Free Hospitalization-Free Time and Quality of Life Benefits with CAR T-cell Therapy in Subgroups of Patients with relapsed/refractory MM: Insights from the KarMMa-3 Trial

2026 · Krina K. Patel, Lin Wang, et al. · Transplantation and Cellular Therapy

Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial

2025 · Krina Patel, Lin Wang, et al. · Blood

Treatment-Free Hospitalization-Free Time With CAR T-Cell Therapy Versus Standard Regimens and Quality of Life Implications in Patients With Relapsed/Refractory MM: Findings From the KarMMa-3 Trial

2025 · Krina Patel, Lin Wang, et al. · Clinical Lymphoma Myeloma & Leukemia

Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients

2024 · Krina K. Patel, Paula Rodríguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia

MM-359 Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients

2024 · Krina Patel, Paula Rodríguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia

P-032 Ide-cel versus standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in the modified intention to-treat (mITT) population

2023 · Salomon Manier, Sikander Ailawadhi, et al. · Clinical Lymphoma Myeloma & Leukemia

P-053 Idecabtagene vicleucel (ide-cel) retreatment response was characterized by poor activation, impaired cellular expansion, and limited cytolytic activity of chimeric antigen receptor (CAR) T cells

2023 · Fan Wu, Ye Shen, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 11

Citation count: 25

H-index: 2

I10-index: 1